Shenpeng Ying

Taizhou Central Hospital — China

Medicine · Health Sciences

12h-index806citations43works4.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(20), HER2/EGFR in Cancer Research(9), Cancer Genomics and Diagnostics(7), Gastric Cancer Management and Outcomes(6), Lung Cancer Research Studies(5)

Publications43 total

A dosimetric correlation between the bladder filling volume and its effects on radiation dose during high-dose-rate intracavitary brachytherapy in patients with cervical cancer
Discover Oncology·2025Open Access
Nanoparticles-mediated mitochondrial relocation of lipid-lowering drugs shape energy metabolism to conquer acquired immune resistance
Drug Resistance Updates·2025· 2 cited
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
The Lancet·2025· 6 cited
Stereotactic body radiation therapy or conventional fractionated radiotherapy combined with immune checkpoint inhibitors? From biological perspectives
Frontiers in Immunology·2025Open Access
Bioinspired Chloride-Assisted Protein Channels: Enhancing Proton Transport for Sustainable Energy Harvesting from Acidic Wastewater
Journal of the American Chemical Society·2025· 16 cited
First Report of NSCLC With IDH1 Mutation: A Case Report
Clinical Lung Cancer·2025
Biomarker Discovery for Early Diagnosis of Papillary Thyroid Carcinoma Using High-Throughput Enhanced Quantitative Plasma Proteomics
Journal of Proteome Research·2023· 9 cited
The application value of circulating tumor DNA methylation biomarkers in early diagnosis of non-small cell lung cancer
Minerva Medica·2023
Supplementary figures from Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
2023Open Access
Supplementary figures from Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
2023· 1 citedOpen Access
Data from Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
2023Open Access
Data from Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
2023Open Access
Supplementary tables from Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
2023Open Access
Supplementary tables from Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
2023Open Access
Individualized estimates of intensity-modulated radiotherapy plans after breast conservation surgery for left-sided breast cancer
World Journal of Surgical Oncology·2023· 2 citedOpen Access
DUSP1 Signaling Pathway Regulates Cytarabine Sensitivity in Acute Myeloid Leukemia
Technology in Cancer Research & Treatment·2023· 1 citedOpen Access
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
JAMA·2022· 418 citedOpen Access
Combination of Tumor Mutational Burden and DNA Damage Repair Gene Mutations with Stromal/Immune Scores Improved Prognosis Stratification in Patients with Lung Adenocarcinoma
Journal of Oncology·2022· 2 citedOpen Access
Cancer-associated fibroblasts induce epithelial-mesenchymal transition of esophageal squamous cell carcinoma through paracrine TGFβ1 signalling
Research Square (Research Square)·2022Open Access
Synthesis of Substituted Pyrimido[1,2‐<i>b</i>]indazoles through (3+2+1) Cyclization of 3‐Aminoindazoles, Ketones, and <i>N</i>,<i>N</i>‐Dimethylaminoethanol as One‐Carbon Synthon
Advanced Synthesis & Catalysis·2022· 16 cited
page 1 of 3Next →

Frequent Co-authors

Zhengbo Song(8), Shiqing Chen(8), Jianjin Huang(8), Dongqing Lv(8), Ting Bei(8), Feng Hua(8), Wenxian Wang(8), C. Xu(8), Chan Gao(8), Shun Lü(8), Yanmei Liu(8), Lingqin Ni(7), Yuping Li(6), Xiaoyu Wu(6), Zhijian Sun(6), Han Han‐Zhang(5), Huali Sun(5), Yan Ding(4), Bo Wu(4), Hongsheng Lu(4)